442 related articles for article (PubMed ID: 18349406)
1. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
Rondanina G; Puntoni M; Severi G; Varricchio C; Zunino A; Feroce I; Bonanni B; Decensi A
J Clin Oncol; 2008 Mar; 26(9):1537-43. PubMed ID: 18349406
[TBL] [Abstract][Full Text] [Related]
2. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM
J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980
[TBL] [Abstract][Full Text] [Related]
3. The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial.
Kinney AY; Richards C; Vernon SW; Vogel VG
Prev Med; 1998; 27(5 Pt 1):713-9. PubMed ID: 9808803
[TBL] [Abstract][Full Text] [Related]
4. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial.
Loehberg CR; Jud SM; Haeberle L; Heusinger K; Dilbat G; Hein A; Rauh C; Dall P; Rix N; Heinrich S; Buchholz S; Lex B; Reichler B; Adamietz B; Schulz-Wendtland R; Beckmann MW; Fasching PA
Breast Cancer Res Treat; 2010 May; 121(1):101-10. PubMed ID: 20306293
[TBL] [Abstract][Full Text] [Related]
6. Physician counseling on hormone replacement therapy and bone loss: do socioeconomic and racial characteristics of women influence counseling?
Neuner JM; McCarthy EP; Davis RB; Phillips RS
J Womens Health (Larchmt); 2003 Jun; 12(5):495-504. PubMed ID: 12869297
[TBL] [Abstract][Full Text] [Related]
7. Participation in a women's breast cancer risk counseling trial. Who participates? Who declines? High Risk Breast Cancer Consortium.
Rimer BK; Schildkraut JM; Lerman C; Lin TH; Audrain J
Cancer; 1996 Jun; 77(11):2348-55. PubMed ID: 8635106
[TBL] [Abstract][Full Text] [Related]
8. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
[TBL] [Abstract][Full Text] [Related]
9. Worry and risk perception of breast cancer in a prevention trial of low dose tamoxifen in midlife postmenopausal hormone users.
Rondanina G; Puntoni M; Guerrieri-Gonzaga A; Marra D; Bonanni B; DeCensi A
Breast; 2017 Aug; 34():108-114. PubMed ID: 28570956
[TBL] [Abstract][Full Text] [Related]
10. Interest in breast cancer chemoprevention among older women.
Tjia J; Micco E; Armstrong K
Breast Cancer Res Treat; 2008 Apr; 108(3):435-53. PubMed ID: 17554628
[TBL] [Abstract][Full Text] [Related]
11. Validation of a model predicting enrollment status in a chemoprevention trial for breast cancer.
Yeomans Kinney A; Vernon SW; Shui W; Weber DV; Schell M; Vogel VG
Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):591-5. PubMed ID: 9681527
[TBL] [Abstract][Full Text] [Related]
12. Choices in cancer treatment: a qualitative study of the older women's (>70 years) perspective.
Husain LS; Collins K; Reed M; Wyld L
Psychooncology; 2008 Apr; 17(4):410-6. PubMed ID: 17847124
[TBL] [Abstract][Full Text] [Related]
13. Cancer prevention trials and primary care physicians: factors associated with recommending trial enrollment.
Battaglia TA; Ash A; Prout MN; Freund KM
Cancer Detect Prev; 2006; 30(1):34-7. PubMed ID: 16476525
[TBL] [Abstract][Full Text] [Related]
14. Stroke risk and tamoxifen therapy for breast cancer.
Geiger AM; Fischberg GM; Chen W; Bernstein L
J Natl Cancer Inst; 2004 Oct; 96(20):1528-36. PubMed ID: 15494603
[TBL] [Abstract][Full Text] [Related]
15. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
Tchou J; Hou N; Rademaker A; Jordan VC; Morrow M
Cancer; 2004 May; 100(9):1800-6. PubMed ID: 15112259
[TBL] [Abstract][Full Text] [Related]
16. Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ.
Yen TW; Kuerer HM; Ottesen RA; Rouse L; Niland JC; Edge SB; Theriault RL; Weeks JC
J Clin Oncol; 2007 Aug; 25(22):3251-8. PubMed ID: 17577019
[TBL] [Abstract][Full Text] [Related]
17. Recruiting high risk women into a breast cancer health promotion trial.
Lerman C; Rimer BK; Daly M; Lustbader E; Sands C; Balshem A; Masny A; Engstrom P
Cancer Epidemiol Biomarkers Prev; 1994; 3(3):271-6. PubMed ID: 8019378
[TBL] [Abstract][Full Text] [Related]
18. Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision making.
Matloff ET; Moyer A; Shannon KM; Niendorf KB; Col NF
J Womens Health (Larchmt); 2006 Sep; 15(7):843-56. PubMed ID: 16999640
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention Indication Score: a user-friendly tool for prevention of breast cancer - pilot analysis.
Layeequr Rahman R; Crawford S
Breast; 2009 Oct; 18(5):289-93. PubMed ID: 19716702
[TBL] [Abstract][Full Text] [Related]
20. Understanding attitudes of older women toward hormone replacement therapy.
Phelan EA; Buist DS; Anderson LA; Newton KM; Delaney KM; LaCroix AZ
Prev Med; 2001 Jan; 32(1):49-56. PubMed ID: 11162326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
